WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call